Healthcare / Medical DevicesTechnical Analysis Guide

BSX Stock Analysis

Boston Scientific Corporation

💡 Quick Answer

Across 4 APEX technical signals, BSX is currently split between bullish and bearish readings — 0 bullish, 0 bearish as of 2026-06-11. Run a live analysis to see the current composite score.

BSX is one of the most consistent large-cap medical device growth stories, with 8+ consecutive years of double-digit organic revenue growth. ATR of 3-4% reflects premium growth expectations.

WATCHMAN Growth: LAAC market leaderRSI Behavior: Growth stock 50-75 rangeElectrophysiology: Farapulse pulsed field

Boston Scientific develops and manufactures minimally invasive medical devices for cardiac rhythm management, electrophysiology, endoscopy, urology, neuromodulation, and peripheral interventions. Its WATCHMAN Left Atrial Appendage Closure (LAAC) device for stroke prevention in atrial fibrillation patients is the fastest-growing high-value product in the cardiac portfolio. Boston Scientific is known for consistent revenue outperformance driven by new product launches and geographic expansion.

LIVE CHART·BSX. DailyPowered by TradingView

📊 Open BSX on TradingView ↗Affiliate link

Get live BSX signal analysis

APEX runs 8 signals on BSX in real time: RSI, MACD, Fibonacci, Volume, and more.

Analyze BSX Now →

Why Do Traders Watch BSX?

BSX is one of the most consistent large-cap medical device growth stories, with 8+ consecutive years of double-digit organic revenue growth. ATR of 3-4% reflects premium growth expectations. Post-earnings moves of 5-8% are typical and tend to be directionally consistent. The company almost never misses its own guidance, creating a reliable "buy the dip" pattern on broad market selloffs. WATCHMAN procedure volumes and electrophysiology system sales are the primary tracking metrics.

Is BSX a Buy Right Now? Current Signal Readings

📊WATCHMAN GrowthLAAC market leader

The WATCHMAN FLX device for LAA closure in AFib patients holds dominant market share and is growing procedure volumes at 20-25% annually as more electrophysiologists are trained and hospital programs expand. Each quarter of WATCHMAN procedure volume growth above 20% drives an incremental positive re-rating of BSX's cardiac rhythm management segment.

📊RSI BehaviorGrowth stock 50-75 range

BSX's consistent earnings beats sustain a higher RSI floor than the average medical device stock. RSI dips to 50-55 during broad market selloffs. While the procedure growth trajectory remains intact. Have been the most reliable BSX entry points, typically producing 12-18% gains over the subsequent quarter.

📊ElectrophysiologyFarapulse pulsed field

BSX's Farapulse pulsed field ablation (PFA) system is winning significant market share in the AFib ablation market against traditional thermal ablation. Each quarterly Farapulse procedure count disclosure and new system installation is a meaningful positive catalyst. PFA is the fastest-growing modality in the $8B electrophysiology market.

📅Earnings Consistency8+ year beat streak

Boston Scientific has beaten consensus EPS estimates for 8+ consecutive years. One of the longest streaks in large-cap medical devices. This consistency means BSX rarely presents a "true" buying opportunity at low prices; instead, the pattern is to buy on broad market pullbacks rather than waiting for individual stock weakness.

📋 BSX Key Stats for Traders

⚡ATR (14-day)3-4% of price

📦Avg daily volume~5-8 million shares

🎯Key metricWATCHMAN volumes + Farapulse adoption

📅Post-earnings move5-8% typical

🔗 Related Stocks

MDT SYK ISRG ABT

Run a live BSX analysis

APEX combines RSI, MACD, Fibonacci, Volume, and 4 more signals into one composite score in under 30 seconds.

Analyze BSX Free →

📊 Advanced charting for BSX on TradingView ↗

💬 Frequently Asked Questions. BSX

QIs BSX a good stock to buy right now?

AWhether BSX is a buy depends on its current technical positioning. BSX is one of the most consistent large-cap medical device growth stories, with 8+ consecutive years of double-digit organic revenue growth. ATR of 3-4% reflects premium growth expectations. Post-earnings moves of 5-8% are typical and tend to be directionally consistent. The company almost never misses its own guidance, creating a reliable "buy the dip" pattern on broad market selloffs. WATCHMAN procedure volumes and electrophysiology system sales are the primary tracking metrics. Run a live APEX analysis at apexstockintel.com to see the current composite score, RSI, and MACD signals. Updated every trading day.

QWhat are the most important technical signals for BSX?

AThe four key signals for BSX are: WATCHMAN Growth (LAAC market leader). The WATCHMAN FLX device for LAA closure in AFib patients holds dominant market share and is growing procedure volumes at 20-25% annually as more electrophysiologists are trained and hospital programs expand. Each quarter of WATCHMAN procedure volume growth above 20% drives an incremental positive re-rating of BSX's cardiac rhythm management segment.. RSI Behavior (Growth stock 50-75 range). BSX's consistent earnings beats sustain a higher RSI floor than the average medical device stock. RSI dips to 50-55 during broad market selloffs. While the procedure growth trajectory remains intact. Have been the most reliable BSX entry points, typically producing 12-18% gains over the subsequent quarter.. Electrophysiology (Farapulse pulsed field). BSX's Farapulse pulsed field ablation (PFA) system is winning significant market share in the AFib ablation market against traditional thermal ablation. Each quarterly Farapulse procedure count disclosure and new system installation is a meaningful positive catalyst. PFA is the fastest-growing modality in the $8B electrophysiology market.. Earnings Consistency (8+ year beat streak). Boston Scientific has beaten consensus EPS estimates for 8+ consecutive years. One of the longest streaks in large-cap medical devices. This consistency means BSX rarely presents a "true" buying opportunity at low prices; instead, the pattern is to buy on broad market pullbacks rather than waiting for individual stock weakness.

QWhat is BSX's RSI telling traders right now?

ABSX's consistent earnings beats sustain a higher RSI floor than the average medical device stock. RSI dips to 50-55 during broad market selloffs. While the procedure growth trajectory remains intact. Have been the most reliable BSX entry points, typically producing 12-18% gains over the subsequent quarter. APEX scores BSX's RSI as part of its 8-factor composite signal. Updated daily.

QHow does BSX behave technically compared to other Healthcare / Medical Devices stocks?

ABSX is in the Healthcare / Medical Devices sector. Boston Scientific develops and manufactures minimally invasive medical devices for cardiac rhythm management, electrophysiology, endoscopy, urology, neuromodulation, and peripheral interventions. Its WATCHMAN Left Atrial Appendage Closure (LAAC) device for stroke prevention in atrial fibrillation patients is the fastest-growing high-value product in the cardiac portfolio. Boston Scientific is known for consistent revenue outperformance driven by new product launches and geographic expansion. Key stats: ATR (14-day): 3-4% of price, Avg daily volume: ~5-8 million shares, Key metric: WATCHMAN volumes + Farapulse adoption, Post-earnings move: 5-8% typical.

QWhat MACD signals work best for BSX?

AMACD measures momentum direction via the relationship between two exponential moving averages. Bullish crossovers (MACD line crossing above the signal line) indicate increasing upward momentum, while bearish crossovers signal the opposite. APEX tracks BSX's MACD histogram direction daily.

OTHER STOCK GUIDES

Technology49

+−